Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea

The goal of this study was to assess the relationship between the severity of obstructive sleep apnoea (OSA) and the levels of carcinogenesis- and tumour growth-related biomarkers in patients with cutaneous melanoma. This multicentre observational study included patients who were newly diagnosed with melanoma. The patients were classified as non-OSA (apnoea–hypopnoea index (AHI) 0–5 events·h−1), mild OSA (AHI 5–15 events·h−1) and moderate–severe OSA (AHI >15 events·h−1). ELISAs were performed to analyse the serum levels of hypoxia- and tumour adhesion-related biomarkers (vascular endothelial growth factor (VEGF), interleukin (IL)-8, intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)-1) and markers of tumour aggressiveness (S100 calcium-binding protein B (S100B) and melanoma inhibitory activity (MIA)). A logistic model adjusted for age, sex and body mass index was fitted to each biomarker, and the AHI served as the dependent variable. 360 patients were included (52.2% male, median (interquartile range) age 55.5 (43.8–68.0) years and AHI 8.55 (2.8–19.5) events·h−1). The levels of VEGF, IL-8, ICAM-1, S100B and MIA were not related to the severity of OSA. The levels of VCAM-1 were higher in patients with OSA than those without OSA (mild OSA: odds ratio (OR) 2.07, p=0.021; moderate–severe OSA: OR 2.35, p=0.013). In patients with cutaneous melanoma, OSA was associated with elevated circulating levels of VCAM-1 that could indicate the contribution of OSA in tumorigenesis via integrin-based adhesion. In patients with cutaneous melanoma, OSA is associated with increased expression of a biomarker of tumorigenesis http://ow.ly/mLo430i9Z8j